AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F18⁸⁵ PE System in Treatment of Pulmonary Embolism October 31st, 2022 Announcements
AngioDynamics Announces FDA Clearance of Expanded Indications for Auryon Atherectomy System August 5th, 2022 Announcements
AngioDynamics, The PERT Consortium™ Launch APEX-AV Study Assessing AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE System in Treatment of Pulmonary Embolism April 28th, 2022 Announcements
New Clinical Study to Assess Auryon Atherectomy Treatment in Below-the-Knee Arteries April 14th, 2022 Announcements
AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022 December 15th, 2021 Announcements
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance September 30th, 2021 Announcements
AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021 September 15th, 2021 Announcements
New AMA Category III CPT Code Issued for Transcatheter Removal/Debulking of Intracardiac Masses August 30th, 2021 Announcements
AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference July 29th, 2021 Announcements
AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results July 13th, 2021 Announcements
AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021 July 8th, 2021 Announcements
AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021 June 24th, 2021 Announcements
AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System June 8th, 2021 Announcements
AngioDynamics to Present at the UBS Virtual Global Healthcare Conference May 17th, 2021 Announcements
AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System April 12th, 2021 Announcements
AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance March 30th, 2021 Announcements
AngioDynamics to Participate in a Virtual Fireside Chat at the KeyBanc Life Sciences & MedTech Investor Forum March 15th, 2021 Announcements
AngioDynamics to Participate in a Virtual Fireside Chat at the Oppenheimer Healthcare Conference March 9th, 2021 Announcements
AngioDynamics Appoints Richard C. Rosenzweig Senior Vice President, General Counsel and Secretary, Promotes Juan Carlos Serna to Senior Vice President, Scientific & Clinical Affairs February 1st, 2021 Announcements
AngioDynamics to Present at the J.P. Morgan Virtual Healthcare Conference January 4th, 2021 Announcements
AngioDynamics Announces Presentation of Positive Safety, Efficacy Results from RAPID Outcomes Database November 12th, 2020 Announcements
AngioDynamics Announces Commercial Launch of Auryon Atherectomy System in United States September 21st, 2020 Announcements
AngioDynamics to Report Fiscal 2021 First Quarter Financial Results on September 29, 2020 September 17th, 2020 Announcements
AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System August 17th, 2020 Announcements
AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference August 3rd, 2020 Announcements
AngioDynamics Receives FDA Clearance and CE Mark for SmartPort+ Implantable Port July 27th, 2020 Announcements
AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results July 16th, 2020 Announcements
AngioDynamics to Report Fiscal 2020 Fourth Quarter and Full-Year Financial Results on July 16, 2020 June 23rd, 2020 Announcements
AngioDynamics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference June 8th, 2020 Announcements
AngioDynamics to Report Fiscal 2020 Third Quarter Financial Results on April 7, 2020 March 10th, 2020 Announcements
AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer February 6th, 2020 Announcements
AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON™ Atherectomy System January 16th, 2020 Announcements
AngioDynamics to Report Fiscal 2020 Second Quarter Financial Results on January 7, 2020 December 10th, 2019 Announcements
AngioDynamics Hosts “Beacon of Hope” Event to Mark Pancreatic Cancer Awareness Month November 5th, 2019 Announcements
AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology October 3rd, 2019 Announcements
AngioDynamics Awarded Premier’s Nationally Outsourced Implantable Infusion Port Agreement September 9th, 2019 Announcements
AngioDynamics to Report Fiscal 2020 First Quarter Financial Results on October 3, 2019 September 5th, 2019 Announcements
AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors July 31st, 2019 Announcements
AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results July 10th, 2019 Announcements
AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019 June 20th, 2019 Announcements
AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference June 4th, 2019 Announcements
AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc. June 3rd, 2019 Announcements
AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange May 28th, 2019 Announcements
AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer May 22nd, 2019 Announcements
AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer May 13th, 2019 Announcements
AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million April 17th, 2019 Announcements
AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer April 17th, 2019 Announcements
AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer April 1st, 2019 Announcements
OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy March 28th, 2019 Announcements
AngioDynamics to Report Fiscal 2019 Third Quarter Financial Results on April 2, 2019 March 12th, 2019 Announcements
AngioDynamics to Present at the Barclays Global Healthcare Conference February 26th, 2019 Announcements
AngioDynamics to Report Fiscal 2019 Second Quarter Financial Results on January 4, 2019 December 10th, 2018 Announcements
AngioDynamics to Present at the Cantor Global Healthcare Conference September 19th, 2018 Announcements
AngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology Portfolio September 13th, 2018 Announcements
AngioDynamics to Report Fiscal 2019 First Quarter Financial Results on September 27, 2018 September 13th, 2018 Announcements
AngioDynamics Provides Updates on Oncology and Vascular Access Businesses August 15th, 2018 Announcements
AngioDynamics to Report Fiscal 2018 Fourth Quarter and Full-Year Financial Results on July 11, 2018 June 21st, 2018 Announcements
